NCT06951841View on ClinicalTrials.gov

Prospective, Single-arm, Phase II Clinical Study of Irinotecan Hydrochloride Liposome Injection Combined With Platinum and Immune Checkpoint Inhibitors Combined With Anlotinib for the Maintenance of Extensive Small Cell Lung Cancer After First-line Induction

PHASE4Not yet recruitingINTERVENTIONAL
Enrollment

31

Participants

Timeline

Start Date

April 30, 2025

Primary Completion Date

May 31, 2026

Study Completion Date

June 30, 2027

Conditions
Small Cell Lung Cancer
Interventions
DRUG

Liposome Irinotecan

Liposome irinotecan(50mg/m\^2) will be administered by intravenous infusion on day 1 in a 3-week treatment cycle

DRUG

Platinum

Carboplatin (AUC 4-5) or Cisplatin (60mg/m\^2) will be administered by intravenous infusion on day 1 in a 3-week treatment cycle

DRUG

Tislelizumab

Tislelizumab (200mg) will be administered by intravenous infusion on day 1 in a 3-week treatment cycle

DRUG

Anlotinib

Anlotinib (8mg) will be administered orally in a 3-week treatment cycle, once a day from day 1 to day 14 of each cycle

Trial Locations (1)

110001

The First Affiliated Hospital of China Medical University, Shenyang

All Listed Sponsors
lead

China Medical University, China

OTHER